Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy

被引:33
作者
Hirvonen, Liisa M. [1 ]
Fruhwirth, Gilbert O. [2 ]
Srikantha, Nishanthan [3 ,4 ]
Barber, Matthew J. [1 ]
Neffendorf, James E. [4 ]
Suhling, Klaus [1 ]
Jackson, Timothy L. [3 ,4 ]
机构
[1] Kings Coll London, Dept Phys, London WC2R 2LS, England
[2] Kings Coll London, St Thomas Hosp, Div Imaging Sci & Biomed Engn, Dept Imaging Chem & Biol, Lambeth Wing, London SE1 7EH, England
[3] Kings Coll London, Sch Med, London SE5 9RS, England
[4] Kings Coll Hosp London, Dept Ophthalmol, London SE5 9RS, England
关键词
fluorescence; hydrodynamic radius; phosphorescence; rotational diffusion; time-resolved anisotropy; TRANSSCLERAL DRUG-DELIVERY; MOLECULAR-WEIGHT; PROTEIN HYDRODYNAMICS; LIVE CELLS; DIFFUSION; MICROSCOPY; SCLERA; SHAPE; FILTRATION; CLEARANCE;
D O I
10.1007/s11095-016-1940-2
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
To measure the hydrodynamic radii of intravitreal anti-VEGF drugs ranibizumab, aflibercept and bevacizumab with mu s time-resolved phosphorescence anisotropy. Ruthenium-based dye Ru(bpy)(2)(mcbpy - O - Su - ester)(PF6)(2), whose lifetime of several hundred nanoseconds is comparable to the rotational correlation time of these drugs in buffer, was used as a label. The hydrodynamic radii were calculated from the rotational correlation times of the Ru(bpy)(2)(mcbpy - O - Su - ester)(PF6)(2)-labelled drugs obtained with time-resolved phosphorescence anisotropy measurements in buffer/glycerol solutions of varying viscosity. The measured radii of 2.76 +/- 0.04 nm for ranibizumab, 3.70 +/- 0.03 nm for aflibercept and 4.58 +/- 0.01 nm for bevacizumab agree with calculations based on molecular weight and other experimental measurements. Time-resolved phosphorescence anisotropy is a relatively simple and straightforward method that allows experimental measurement of the hydrodynamic radius of individual proteins, and is superior to theoretical calculations which cannot give the required accuracy for a particular protein.
引用
收藏
页码:2025 / 2032
页数:8
相关论文
共 49 条
[1]  
Alster Y, 2012, WO Patent App. PCT/ US2011/ 061,535, Patent No. 2011061535
[2]  
Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
[3]  
Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
[4]   Transscleral drug delivery to the retina and choroid [J].
Ambati, J ;
Adamis, AP .
PROGRESS IN RETINAL AND EYE RESEARCH, 2002, 21 (02) :145-151
[5]   CHARACTERIZATION OF PROTEINS AND OTHER MACROMOLECULES BY AGAROSE-GEL CHROMATOGRAPHY [J].
AXELSSON, I .
JOURNAL OF CHROMATOGRAPHY, 1978, 152 (01) :21-32
[6]  
Baggaley E, 2014, LUMINESCENT PHOTOACT, P205
[7]   HINDERED DIFFUSION OF DEXTRAN AND FICOLL IN MICROPOROUS MEMBRANES [J].
BOHRER, MP ;
PATTERSON, GD ;
CARROLL, PJ .
MACROMOLECULES, 1984, 17 (06) :1170-1173
[8]   Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008 [J].
Bunce, C. ;
Xing, W. ;
Wormald, R. .
EYE, 2010, 24 (11) :1692-1699
[9]   Treatment of posterior uveitis with a fluocinolone acetonide implant - Three-year clinical trial results [J].
Callanan, David G. ;
Jaffe, Glenn J. ;
Martin, Daniel F. ;
Pearson, Andrew ;
Comstock, Timothy L. .
ARCHIVES OF OPHTHALMOLOGY, 2008, 126 (09) :1191-1201
[10]   Nuclease resistance of telomere-like oligonucleotides monitored in live cells by fluorescence anisotropy imaging [J].
Cao, ZH ;
Huang, CC ;
Tan, WH .
ANALYTICAL CHEMISTRY, 2006, 78 (05) :1478-1484